Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small-cell Lung Cancer

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works

Cancer statistics, 2015

Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854 · see citing works

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · see citing works

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · see citing works

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489 · see citing works

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090 · see citing works

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081 · see citing works

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations

Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228 · see citing works

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373 · see citing works

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

Mitsudomi, T., Kosaka, T., Endoh, H., Horio, Y., Hida, T., Mori, S., Hatooka, S., Shinoda, M., Takahashi, T., & Yatabe, Y. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.992 · Cited by 938 · see citing works

Screening by Chest Radiograph and Lung Cancer Mortality

Oken, M. M., Hocking, W. G., Kvale, P. A., Andriole, G. L., Buys, S. S., Church, T. R., Crawford, E. D., Fouad, M. N., Isaacs, C. J., Reding, D. J., et al. (2011) · JAMA · doi:10.1001/jama.2011.1591 · Cited by 646 · see citing works

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications

Yasuda, H., Kobayashi, S., & Costa, D. B. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70129-2 · Cited by 610 · see citing works

Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

Yasuda, H., Park, E., Yun, C.-H., Sng, N. J., Lucena-Araujo, A. R., Yeo, W.-L., Huberman, M. S., Cohen, D. W., Nakayama, S., Ishioka, K., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007205 · Cited by 571 · see citing works

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

Inoue, A., Suzuki, T., Fukuhara, T., Maemondo, M., Kimura, Y., Morikawa, N., Watanabe, H., Saijo, Y., & Nukiwa, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4692 · Cited by 509 · see citing works

<i>EGFR</i> Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

Arcila, M. E., Nafa, K., Chaft, J. E., Rekhtman, N., Lau, C., Reva, B. A., Zakowski, M. F., Kris, M. G., & Ladanyi, M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0620 · Cited by 473 · see citing works

Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer

Wu, J.-Y., Yu, C.-J., Chang, Y.-C., Yang, C.-H., Shih, J.-Y., & Yang, P.-C. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3408 · Cited by 463 · see citing works

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

Oxnard, G. R., Lo, P. C., Nishino, M., Dahlberg, S. E., Lindeman, N. I., Butaney, M., Jackman, D. M., Johnson, B. E., & Jänne, P. A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182779d18 · Cited by 360 · see citing works

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt418 · Cited by 324 · see citing works

Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response

Wu, J.-Y., Wu, S.-G., Yang, C.-H., Gow, C.-H., Chang, Y.-L., Yu, C.-J., Shih, J.-Y., & Yang, P.-C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5123 · Cited by 319 · see citing works

Fifty years of cancer incidence: CI5 I–IX

Parkin, D. M., Ferlay, J., Curado, M. P., Bray, F., Edwards, B. K., Shin, H., & Forman, D. (2010) · International Journal of Cancer · doi:10.1002/ijc.25517 · Cited by 242 · see citing works

Specific EGFR Mutations Predict Treatment Outcome of Stage IIIB/IV Patients With Chemotherapy-Naive Non–Small-Cell Lung Cancer Receiving First-Line Gefitinib Monotherapy

Yang, C.-H., Yu, C., Shih, J., Chang, Y., Hu, F., Tsai, M.-C., Chen, K., Lin, Z., Huang, C.-J., Shun, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6695 · Cited by 235 · see citing works

Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib

Naidoo, J., Sima, C. S., Rodriguez, K., Busby, N., Nafa, K., Ladanyi, M., Riely, G. J., Kris, M. G., Arcila, M. E., & Yu, H. A. (2015) · Cancer · doi:10.1002/cncr.29493 · Cited by 211 · see citing works

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers

Costa, D. B., Kobayashi, S., Tenen, D. G., & Huberman, M. S. (2007) · Lung Cancer · doi:10.1016/j.lungcan.2007.05.017 · Cited by 160 · see citing works

<i>EGFR</i> Exon 19 Insertions: A New Family of Sensitizing <i>EGFR</i> Mutations in Lung Adenocarcinoma

He, M., Capelletti, M., Nafa, K., Yun, C.-H., Arcila, M. E., Miller, V. A., Ginsberg, M. S., Zhao, B., Kris, M. G., Eck, M. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2361 · Cited by 149 · see citing works

Activity of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Patients with Non-small Cell Lung Cancer Harboring Rare Epidermal Growth Factor Receptor Mutations

De Pas, T., Toffalorio, F., Manzotti, M., Fumagalli, C., Spitaleri, G., Catania, C., Delmonte, A., Giovannini, M., Spaggiari, L., de Braud, F., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318227e8c6 · Cited by 138 · see citing works

Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma

Wu, S.-G., Gow, C.-H., Yu, C., Chang, Y., Yang, J. C., Hsu, Y., Shih, J.-Y., Lee, Y.-C., & Yang, P. (2008) · European Respiratory Journal · doi:10.1183/09031936.00167407 · Cited by 127 · see citing works

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: Focus on epidermal growth factor receptor mutation testing and mutation-positive patients

Roengvoraphoj, M., Tsongalis, G. J., Dragnev, K. H., & Rigas, J. R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.05.001 · Cited by 120 · see citing works

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR

Wu, S., Kuo, Y.-W., Chang, Y., Shih, J., Chen, Y., Tsai, M., Yu, C., Yang, C.-H., & Yang, P. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182370e30 · Cited by 90 · see citing works

EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids

Chen, Z., Feng, J., Saldivar, J.-S., Gu, D., Bockholt, A., & Sommer, S. S. (2008) · Oncogene · doi:10.1038/onc.2008.71 · Cited by 81 · see citing works

Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature

Gu, D., Scaringe, W. A., Li, K., Saldivar, J., Hill, K. A., Chen, Z., Hagman, K. D. F., & Sommer, S. S. (2007) · Human Mutation · doi:10.1002/humu.20512 · Cited by 60 · see citing works

EGFR Exon 20 Insertion A763-Y764insFQEA and Response to Erlotinib—Letter

Voon, P. J., Tsui, D. W. Y., Rosenfeld, N., & Chin, T. M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0192 · Cited by 47 · see citing works

Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion

Tsai, T.-H., Wu, S., Hsieh, M., Yu, C., Yang, J. C., & Shih, J. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.02.018 · Cited by 46 · see citing works

Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy

Tsai, T.-H., Yang, C., Ho, C., Liao, W., Jan, I., Chen, K., Wang, J., Ruan, S., Yu, C., Yang, J. C., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.10.005 · Cited by 35 · see citing works

Efficacy of Gefitinib for Elderly Patients with Advanced Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Gene Mutations: A Retrospective Analysis

Uruga, H., Kishi, K., Fujii, T., Beika, Y., Enomoto, T., Takaya, H., Miyamoto, A., Morokawa, N., Kurosaki, A., & Yoshimura, K. (2010) · Internal Medicine · doi:10.2169/internalmedicine.49.2531 · Cited by 34 · see citing works

EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.

Yu, G., Xie, X., Sun, D., Geng, J., Fu, F., Zhang, L., & Wang, H. (2015) · PubMed Central · Cited by 26 · see citing works

Lung Carcinomas with EGFR Exon 19 Insertions Are Sensitive to Gefitinib Treatment

Iyevleva, A. G., Mitiushkina, N. V., Karaseva, N. A., Орлов, С. В., Volodina, L. N., Kulikova, Y. E., Lozhkina, A. M., Ivantsov, A. O., Tiurin, V. I., Togo, A. V., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000106 · Cited by 17 · see citing works

An Uncommon Insertion Mutation in Exon 19 of EGFR Showed Stable Disease after TKI Treatment

Chan, A. W. H., Tong, J. H. M., Lo, S.-H., & To, K. F. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182a471e0 · Cited by 9 · see citing works

EGFR Exon 19 Insertions Show Good Response to Gefitinib, but Short Time to Progression in Japanese Patients

Jangchul, P., Kondo, C., Shimizu, J., Horio, Y., Yoshida, K., & Hida, T. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182a735cc · Cited by 8 · see citing works

Different clinical effects upon separate inhibition of coexisting EGFR and PI3KCA mutations in a lung adenocarcinoma patient

Tiseo, M., Bersanelli, M., Perrone, F., Tamborini, E., Settanni, G., Busico, A., Rossi, G., Ardizzoni, A., & Pelosi, G. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.12.008 · Cited by 7 · see citing works

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases

Yang, J. C., Schüler, M., Popat, S., Miura, S., Heeke, S., Park, K., Märten, A., & Kim, E. S. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.126 · Cited by 276 · see citing works

Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations

Passaro, A., Mok, T. S. K., Peters, S., Popat, S., Ahn, M., & de Marinis, F. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.002 · Cited by 215 · see citing works

Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance

Santoni‐Rugiu, E., Melchior, L. C., Urbanska, E. M., Jakobsen, J. N., de Stricker, K., Grauslund, M., & Sørensen, J. B. (2019) · Cancers · doi:10.3390/cancers11070923 · Cited by 195 · see citing works

The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal

Gristina, V., Malapelle, U., Galvano, A., Pisapia, P., Pepe, F., Rolfo, C. D., Tortorici, S., Bazan, V., Troncone, G., & Russo, A. D. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101994 · Cited by 123 · see citing works

Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario

Russo, A., Franchina, T., Ricciardi, G., Battaglia, A., Picciotto, M., & Adamo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061431 · Cited by 110 · see citing works

Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes

John, T., Taylor, A., Wang, H., Eichinger, C. S., Freeman, C. S., & Ahn, M. (2021) · Cancer Epidemiology · doi:10.1016/j.canep.2021.102080 · Cited by 80 · see citing works

EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP)

Cardona, A. F., Rojas, L., Zatarain-Barrón, Z. L., Freitas, H., Granados, S. T., Castillo, O., Oblitas, G., Corrales, L., Castro, C. D., Ruíz-Patiño, A., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.10.007 · Cited by 63 · see citing works

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations

Lin, Y., Chen, J., Liao, W., Ho, C., Hsu, C., Yang, C., Chen, K., Lee, J., Lin, Z., Shih, J., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.32025 · Cited by 62 · see citing works

Effectiveness of Treatments for Advanced Non–Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations

Wu, J., Yu, C., & Shih, J. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.06.018 · Cited by 58 · see citing works

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea

Byeon, S., Kim, Y., Lim, S. W., Cho, J. H., Park, S., Lee, J., Sun, J., Choi, Y., Lee, S., Ahn, J. S., et al. (2018) · Cancer Research and Treatment · doi:10.4143/crt.2018.151 · Cited by 54 · see citing works

Concomitant driver mutations in advanced <i>EGFR</i> -mutated non-small-cell lung cancer and their impact on erlotinib treatment

Jakobsen, J. N., Santoni-Rugiu, E., Grauslund, M., Melchior, L., & Sørensen, J. B. (2018) · Oncotarget · doi:10.18632/oncotarget.25490 · Cited by 42 · see citing works

Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study

on behalf of AME Lung Cancer Collaborative Group, Xu, C., Wang, W., Wang, D., Wang, Q., Pu, X., Zhu, Y., Huang, J., Yu, Z., Cui, Z., et al. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-382 · Cited by 40 · see citing works

Outcomes of cancer therapy administered to treatment-naïve lung cancer patients in the intensive care unit

Chen, Y., Lin, J., Ho, C., Yang, C., Chang, C., Huang, T., Chen, C., Chen, K., Shih, J., & Yu, C. (2017) · Journal of Cancer · doi:10.7150/jca.18178 · Cited by 27 · see citing works

Genetic alterations shaping tumor response to anti-EGFR therapies

Vaquero, J., Pavy, A., Gonzalez‐Sanchez, E., Meredith, M., Arbelaiz, A., & Fouassier, L. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100863 · Cited by 24 · see citing works

Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer

Lin, Y., Tsai, T.-H., Wu, S., Liu, Y., Yu, C., & Shih, J. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.04.022 · Cited by 23 · see citing works

Single‐Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK‐788) in Healthy Volunteers: Low‐Fat Meal Effect and Relative Bioavailability of 2 Capsule Products

Zhang, S., Jin, S., Griffin, C., Feng, Z., Lin, J., Baratta, M., Brake, R. L., Venkatakrishnan, K., & Gupta, N. (2021) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.951 · Cited by 18 · see citing works

Multiplexed molecular profiling of lung cancer with malignant pleural effusion using next generation sequencing in Chinese patients

Ruan, X., Sun, Y., Wang, W., Ye, J., Zhang, D., Gong, Z., & Yang, M. (2020) · Oncology Letters · doi:10.3892/ol.2020.11446 · Cited by 15 · see citing works

Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months’ survival

Chan, R. T. (2018) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12853 · Cited by 14 · see citing works

Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients

Malapelle, U., Pilotto, S., Reale, M. L., Passiglia, F., Pisapia, P., Pepe, F., Belluomini, L., Galetta, D., Cortinovis, D. L., Tiseo, M., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103536 · Cited by 13 · see citing works

Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer

Gao, X., Wei, X., Zheng, M.-Y., Chen, Z.-H., Zhang, X., Zhong, W., Yang, J., Wu, Y.-L. L. C., & Zhou, Q. H. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-20-1630 · Cited by 11 · see citing works

Real-world treatment patterns and outcomes among patients with advanced non-small-cell lung cancer with spindle cell and/or giant cell carcinoma

Chang, C., Hsieh, M., Shih, J., Lee, Y., Liao, W., Hsu, C., Yang, C., Chen, K., Lee, J., Ho, C., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221133889 · Cited by 10 · see citing works

Comprehensive Genomic Analysis of Patients With Non–Small-Cell Lung Cancer Using Blood-Based Circulating Tumor DNA Assay: Findings From the BFAST Database of a Single Center in Taiwan

Wang, H.-Y., Ho, C., Lin, Y., Liao, W., Chen, C., Shih, J., & Yu, C. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00314 · Cited by 10 · see citing works

Real-world analysis of survival outcomes in advanced EGFR-mutant NSCLC patients treated with platinum-pemetrexed after EGFR-TKI treatment failure

Yao, Z.-H., Liao, W., Yang, C.-Y., Ho, C., Shih, J., Chen, K., Yang, J. C., & Yu, C. (2024) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2024.08.017 · Cited by 9 · see citing works

Epidermal growth factor receptor mutations in non–small cell lung cancer undetected by high-sensitivity allele-specific real-time polymerase chain reaction–based assays

Shen, C., Ho, H., Yeh, Y., Chiu, C., & Chou, T. (2020) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000277 · Cited by 6 · see citing works

Efficacy of EGFR-TKI sequential therapy in patients with EGFR exon 19 insertion-positive non-small-cell lung cancer: A case report

Shan, B., Li, Y., Zhao, C., An, X., & Zhang, Q.-M. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i6.1883 · Cited by 6 · see citing works

Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review

Watanabe, N., Horio, Y., & Fujiwara, Y. (2022) · Annals of Translational Medicine · doi:10.21037/atm-2022-56 · Cited by 5 · see citing works

EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors

Shaffer, W., Kobayashi, I. S., Sentana‐Lledo, D., Sundararaman, S. K., Lee, M. D., Rangachari, D., VanderLaan, P. A., Kobayashi, S. S., & Costa, D. B. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107250 · Cited by 5 · see citing works

Not All EGFR Exon 20 Insertions Are Created Equal

Lin, Y., & Shih, J. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100069 · Cited by 5 · see citing works

Cutting edge therapies: A review of Food and Drug Administration‐ approved drugs for non‐small cell lung cancer

Mutukuru, M., Kandula, S. R., Ramakrishna, V., Sanka, P., Sidde, G. P., Muzzamil, S. M., Uppara, H. B., & Prasad, P. D. (2026) · International Journal of Cancer · doi:10.1002/ijc.70318 · Cited by 4 · see citing works

Advances in the Treatment of Rare Epidermal Growth Factor Receptor Mutations in Advanced Nonsmall-Cell Lung Cancer

Yu, L., Wang, R., Zhao, Y., Wu, Y., Wang, L., Chen, H., He, Z., Wang, Q., & Wu, Y. (2023) · Technology in Cancer Research & Treatment · doi:10.1177/15330338231168466 · Cited by 4 · see citing works

Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions

Li, Y., Ni, Y., Lv, F., Shi, Y., Chen, Y., Wu, X., Pang, J., Huang, L., Shao, Y. W., Wang, T., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04075-1 · Cited by 3 · see citing works

[A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer with Uncommon EGFR Mutations].

Du, W., Wo, Y., Lu, T., Wang, Y., & Jiao, W. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.09.07 · Cited by 3 · see citing works

Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib

Zhu, Y., Du, K., Wang, W., Song, Z., Xu, C., Chen, G., Zhuang, W., Lv, T., & Song, Y. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.04.019 · Cited by 3 · see citing works

A Patient of Advanced NSCLC with a New EGFR Exon 19 Insertion Mutation and its Response to EGFR-TKIs

Zhu, N., Dong, C., Weng, S., Yuan, Y., & Yuan, Y. (2019) · Journal of College of Physicians And Surgeons Pakistan · doi:10.29271/jcpsp.2019.12.s126 · Cited by 3 · see citing works

Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations

Chang, G., Lam, D. C.-L., Tsai, C., Chen, Y., Shih, J., Aggarwal, S., Wang, S., Kim, S., Kim, Y., Wahid, I., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-021-01869-0 · Cited by 3 · see citing works

The association of EGFR amplification with aberrant exon 20 insertion report using the cobas EGFR Mutation Test v2

Zhang, M.-S., Yeh, Y., Huang, H., Lin, L.-W., Huang, Y.-L. O., Wang, L., Yao, L.-J., Hung, T.-C., Tseng, Y., Lee, Y., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0301120 · Cited by 2 · see citing works

Genomic Applications in Pulmonary Malignancies

Büttner, R., Odenthal, M., & Merkelbach‐Bruse, S. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0727-4_24 · Cited by 1 · see citing works

Genomic Applications in Pulmonary Malignancies

Büttner, R., Heydt, C., & Merkelbach‐Bruse, S. (2018) · Springer eBooks · doi:10.1007/978-3-319-96830-8_27 · Cited by 1 · see citing works

Outcomes of Afatinib in Non-small Cell Lung Cancer Patients Harboring Uncommon Epidermal Growth Factor Receptor MutationsPreprint

Zhao, K., Hu, S., Wei, D., Chen, W., Song, Y., & Wang, C. (2020) · doi:10.21203/rs.3.rs-67709/v1

Long-term survival with pemetrexed-based chemotherapy in a patient with metastatic lung adenocarcinoma of unclear primary origin harboring MTHFR C677T(T/T) mutation: a case report

Yu, Y., Li, N., & Wang, J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1435357

Efficacy of EGFR tyrosine kinase inhibitors in patients with non–small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)

Uehara, Y., Izumi, H., Kobayashi, I. S., Matsumoto, S., Hosomi, Y., Okuno, T., Sugisaka, J., Takase, N., Taima, K., Sasaki, S., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108479

Unraveling Survival Determinants in Patients with Advanced Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertions

Wang, K.-Y., Chang, S.-C., Wei, Y., Hung, J.-C., Chen, C., & Chang, C. (2025) · Current Oncology · doi:10.3390/curroncol32030174

Effects of antihypertensive drugs on the metabolism of mobocertinib in rats both in vitro and in vivo

Yi, D., Ye, J., Lu, Z., Lu, L., Qi, T., Luo, T., Peng, X., Mamun, A. A., Zhou, Q., Chen, D., et al. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100094

Est-il possible de réduire la durée de l’antibiothérapie des exacerbations de BPCO chez les patients hospitalisés ?

Vandenbos, F., Caisso, C., Harb, E. A., Vidal, R., Nicolle, I., Risso, K., & Roger, P. (2017) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.01.004

Effectiveness of Treatments for Advanced Non–Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations

Wu, J., Yu, C., & Shih, J. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.06.018 · Cited by 58 · see citing works

Abstract 23: Sensitivity of EGFR exon 20 insertion mutations to EGFR inhibitors is determined by their location within the tyrosine kinase domain of EGFR

Yasuda, H., Sng, N., Yeo, W.-L., de Figueiredo‐Pontes, L. L., Kobayashi, S. S., & Costa, D. B. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-23 · Cited by 6 · see citing works

Getting out of a wheelchair: an uncommon insertion mutation in exon 19 of EGFR responsive to erlotinib

Agbarya, A., Melamed‐Frank, M., Kaidar‐Person, O., Goldberg-Cohen, I., Nasrallah, H., Wollner, M., Bar, J., Rennert, G., & Lejbkowicz, F. (2014) · SpringerPlus · doi:10.1186/2193-1801-3-507 · Cited by 5 · see citing works

Efficacy of EGFR tyrosine kinase inhibitors in patients with non–small cell lung cancer with EGFR exon 19 insertions: clinical-genomic, preclinical analysis through LC-SCRUM-Asia (multi-institutional genomic screening registry)

Uehara, Y., Izumi, H., Kobayashi, I. S., Matsumoto, S., Hosomi, Y., Okuno, T., Sugisaka, J., Takase, N., Taima, K., Sasaki, S., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108479